Millennium Magazine_7th Ed

194 Millennium - A Marquis Who’s Who Magazine HEALTH AND WELLNESS D r. I. Craig Henderson graduated from Grinnell College with a BA in 1963 and from Columbia University with an MD in 1970. After completing an internship and residency, he went to the National Cancer Institute as a research associate before finishing his medical oncology training at the Dana Farber Cancer Institute, Harvard Medical School, where he continued on the faculty from 1975 to 1992. While there, he founded the Breast Evaluation Center, one of the first multidisciplinary programs of this type. Currently a professor of medicine at the University of California San Francisco, Dr. Henderson served as deputy director of the San Francisco Cancer Center in its earliest stages before moving onto entrepreneurial roles at various pharmaceutical companies, including chief executive officer at Sequus Pharmaceutical, board member of Alza, chief executive officer of Access Oncology and president of Keryx Biopharmaceuticals until 2008. Dr. Henderson chaired the Oncologic Drugs Advisory Committee of the FDA, was on the World Health Organization’s Essential Drugs Committee, was a founding chairman of the Early Breast Cancer Trialists’ Collaborative Group at Oxford, and has been a member of the medical advisory panel of the National Blue Cross-Blue Shield Association for nearly 30 years. Civically involved, he is an advocate of the performing arts and has been on the board of the San Francisco Opera since 2001. Dr. Henderson has notable research accomplishments. He was a principal investigator (PI) on the first phase II study of Herceptin, one of the first targeted therapies. At one time, he was a lone voice advocating randomized clinical trials to evaluate high dose chemotherapy and bone marrow transplants; these trials eventually demonstrated that this therapy had limited to no value for any stage of breast cancer. He was the PI of the national study that established the value of paclitaxel in early breast cancer, and he directed the development of Doxil, the first liposomal drug approved for cancer by the FDA. A fellow of the American College of Physicians, Dr. Henderson has been repeatedly been named one of the Best Doctors in America since 1992. DR. I. CRAIG HENDERSON ONCOLOGIST, RESEARCHER San Francisco, CA